Overview

RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer

Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This study is to investigate the efficacy and safety of rhGM-CSF as adjuvant immunotherapy for patients with resectable stage III colon cancers.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Treatments:
Molgramostim